Stefan Costinean

List of Publications by Year
in descending order

35	7,898	172457	361022
papers	citations	29 h-index	35 g-index

36	36	36	12309
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Promoter Hypomethylation and Expression Is Conserved in Mouse Chronic Lymphocytic Leukemia Induced by Decreased or Inactivated Dnmt3a. Cell Reports, 2016, 15, 1190-1201.	6.4	32
2	MicroRNA-29b mediates altered innate immune development in acute leukemia. Journal of Clinical Investigation, 2016, 126, 4404-4416.	8.2	51
3	Regulated Expression of miR-155 is Required for iNKT Cell Development. Frontiers in Immunology, 2015, 6, 140.	4.8	22
4	Disruption of miR-29 Leads to Aberrant Differentiation of Smooth Muscle Cells Selectively Associated with Distal Lung Vasculature. PLoS Genetics, 2015, 11, e1005238.	3.5	58
5	miR-15b/16-2 deletion promotes B-cell malignancies. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11636-11641.	7.1	98
6	MicroRNA 29 Targets Nuclear Factor-Î¹Bâ€“Repressing Factor and Claudin 1 to Increase Intestinal Permeability. Gastroenterology, 2015, 148, 158-169.e8.	1.3	162
7	Gradual Rarefaction of Hematopoietic Precursors and Atrophy in a Depleted microRNA 29a, b and c Environment. PLoS ONE, 2015, 10, e0131981.	2.5	3
8	Microrna 29b Mediates Immune Evasion of Natural Killer Cells in Acute Myeloid Leukemia. Blood, 2015, 126, 207-207.	1.4	0
9	Pluripotent Stem Cell miRNAs and Metastasis in Invasive Breast Cancer. Journal of the National Cancer Institute, 2014, 106, .	6.3	37
10	Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 4536-4541.	7.1	181
11	Hepatic Loss of miR-122 Predisposes Mice to Hepatobiliary Cyst and Hepatocellular Carcinoma upon Diethylnitrosamine Exposure. American Journal of Pathology, 2013, 183, 1719-1730.	3.8	26
12	Overexpression of miR-155 causes expansion, arrest in terminal differentiation and functional activation of mouse natural killer cells. Blood, 2013, 121, 3126-3134.	1.4	57
13	miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the EÂµ-miR-155 transgenic mouse model. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 20047-20052.	7.1	121
14	miR-29ab1 Deficiency Identifies a Negative Feedback Loop Controlling Th1 Bias That Is Dysregulated in Multiple Sclerosis. Journal of Immunology, 2012, 189, 1567-1576.	0.8	161
15	miR-155 regulates IFN-Î³ production in natural killer cells. Blood, 2012, 119, 3478-3485.	1.4	177
16	Hepatic mi<scp>R</scp>â€29ab1 expression modulates chronic hepatic injury. Journal of Cellular and Molecular Medicine, 2012, 16, 2647-2654.	3.6	50
17	Primary intrathyroidal paraganglioma: histopathology and novel molecular alterations. Human Pathology, 2012, 43, 2371-2375.	2.0	9
18	Regulation of acute graft-versus-host disease by microRNA-155. Blood, 2012, 119, 4786-4797.	1.4	128

#	Article	IF	Citations
19	Stem cell-related markers in primary breast cancers and associated metastatic lesions. Modern Pathology, 2012, 25, 949-955.	5.5	33
20	Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. Journal of Clinical Investigation, 2012, 122, 2871-2883.	8.2	666
21	Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 4908-4913.	7.1	226
22	Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features. Breast Cancer Research and Treatment, 2011, 129, 421-432.	2.5	46
23	Common Fragile Site Tumor Suppressor Genes and Corresponding Mouse Models of Cancer. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-10.	3.0	19
24	Reprogramming of miRNA networks in cancer and leukemia. Genome Research, 2010, 20, 589-599.	5.5	331
25	Modulation of mismatch repair and genomic stability by miR-155. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6982-6987.	7.1	306
26	Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 12210-12215.	7.1	167
27	Fragile histidine triad protein, WW domainâ€containing oxidoreductase protein Wwox, and activator protein 2Î³ expression levels correlate with basal phenotype in breast cancer. Cancer, 2009, 115, 899-908.	4.1	41
28	Src homology 2 domainâ€“containing inositol-5-phosphatase and CCAAT enhancer-binding protein Î² are targeted by miR-155 in B cells of EÎ¼-MiR-155 transgenic mice. Blood, 2009, 114, 1374-1382.	1.4	278
29	Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood, 2009, 114, 3872-3879.	1.4	179
30	MicroRNAs, the immune system and rheumatic disease. Nature Clinical Practice Rheumatology, 2008, 4, 534-541.	3.2	117
31	Targeted deletion of Wwox reveals a tumor suppressor function. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3949-3954.	7.1	210
32	MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 15805-15810.	7.1	1,538
33	Modulation of miR-155 and miR-125b Levels following Lipopolysaccharide/TNF-Î± Stimulation and Their Possible Roles in Regulating the Response to Endotoxin Shock. Journal of Immunology, 2007, 179, 5082-5089.	0.8	1,229
34	Effect of Rapamycin on Mouse Chronic Lymphocytic Leukemia and the Development of Nonhematopoietic Malignancies in EÎ¼-TCL1 Transgenic Mice. Cancer Research, 2006, 66, 915-920.	0.9	69
35	Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in EÎ¼-miR155 transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7024-7029.	7.1	1,023